A federal jury in Seattle has awarded nearly $6 million to a former Biogen (BIIB) sales rep who claimed she was fired after complaining about being pressured to pursue off-label marketing for a multiple sclerosis treatment.

In her lawsuit, Danita Erickson contended that, in the fall of 2017, Biogen sought to ensure that Zinbryta was prescribed by a hematologist for a patient with aplastic anemia — a condition in which the body does not produce enough blood cells — and who was also on Medicare. However, the medicine was only approved for treating relapsing multiple sclerosis patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Glad she raised a ruckus. Predatory marketing practices are all too common and leaving off-label descriptions to the pharmacy companies is leaving the fox in the chicken coop. Yeah, I know, their integrity is without question 🤪 Next …

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy